Iovance Biotherapeutics, Inc. Stock price
Equities
IOVA
US4622601007
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.03 USD | +0.86% | -10.64% | +72.57% |
Financials (USD)
Sales 2024 * | 161M | Sales 2025 * | 413M | Capitalization | 3.92B |
---|---|---|---|---|---|
Net income 2024 * | -352M | Net income 2025 * | -245M | EV / Sales 2024 * | 23.4 x |
Net cash position 2024 * | 133M | Net cash position 2025 * | 251M | EV / Sales 2025 * | 8.88 x |
P/E ratio 2024 * |
-10.8
x | P/E ratio 2025 * |
-19.5
x | Employees | 557 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.06% |
Latest transcript on Iovance Biotherapeutics, Inc.
1 day | +0.86% | ||
1 week | -10.64% | ||
Current month | -11.82% | ||
1 month | +53.33% | ||
3 months | +80.33% | ||
6 months | +166.22% | ||
Current year | +72.57% |
Managers | Title | Age | Since |
---|---|---|---|
Frederick Vogt
CEO | Chief Executive Officer | 50 | 16-09-29 |
Director of Finance/CFO | 51 | 20-12-13 | |
Brian Shew
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Merrill McPeak
BRD | Director/Board Member | 88 | 11-07-19 |
Director/Board Member | 56 | 16-06-06 | |
Michael Weiser
BRD | Director/Board Member | 61 | 18-03-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.95% | 11 M€ | -6.03% | - | |
0.93% | 0 M€ | 0.00% | - | |
0.14% | 0 M€ | 0.00% | - | |
0.11% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 14.03 | +0.86% | 6,482,929 |
24-03-15 | 13.91 | -2.11% | 18,149,736 |
24-03-14 | 14.21 | -3.53% | 7,045,126 |
24-03-13 | 14.73 | +0.07% | 6,399,414 |
24-03-12 | 14.72 | -2.52% | 7,218,117 |
Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+72.57% | 3.89B | |
-20.44% | 10.48B | |
-6.29% | 2.47B | |
-35.49% | 2.16B | |
-21.56% | 1.58B | |
+21.53% | 1.02B | |
+5.46% | 845M | |
-17.58% | 525M | |
-35.10% | 470M | |
+10.80% | 257M |